Share this video  

WCLC 2022 | Antibody-drug conjugates (ADCs) in NSCLC

Byoung Chul Cho, MD, PhD , Yonsei University College of Medicine in Seoul, Republic of Korea, Provides an overview of the mechanism of action of antibody-drug conjugates (ADCs), commenting on the activity of HER2-targeting ADCs in advanced-stage non-small cell lung cancer (NSCLC). ADCs have additionally shown encouraging activity targeting TROP2 in NSCLC in advanced-stage settings. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.